Literature DB >> 26082334

Clinical and morphologic features in five post-polycythemic myelofibrosis patients treated with ruxolitinib.

Alessandra Iurlo1, Daniele Cattaneo, Leonardo Boiocchi, Nicola Orofino, Elisa Fermo, Agostino Cortelezzi, Umberto Gianelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26082334     DOI： 10.1007/s00277-015-2429-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  2 in total

Review 1.  Treatment of Myelofibrosis: Old and New Strategies.

Authors:  Alessandra Iurlo; Daniele Cattaneo
Journal:  Clin Med Insights Blood Disord       Date:  2017-03-08

2.  Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.

Authors:  Hans Michael Kvasnicka; Jürgen Thiele; Carlos E Bueso-Ramos; William Sun; Jorge Cortes; Hagop M Kantarjian; Srdan Verstovsek
Journal:  J Hematol Oncol       Date:  2018-03-15       Impact factor: 17.388
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.